These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 17409205)

  • 1. Frequent occult infection with Cytomegalovirus in cardiac transplant recipients despite antiviral prophylaxis.
    Potena L; Holweg CT; Vana ML; Bashyam L; Rajamani J; McCormick AL; Cooke JP; Valantine HA; Mocarski ES
    J Clin Microbiol; 2007 Jun; 45(6):1804-10. PubMed ID: 17409205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients.
    Mengelle C; Rostaing L; Weclawiak H; Rossignol C; Kamar N; Izopet J
    J Med Virol; 2015 May; 87(5):836-44. PubMed ID: 25655981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus infection in heart transplantation: A single center experience.
    Echenique IA; Angarone MP; Rich JD; Anderson AS; Stosor V
    Transpl Infect Dis; 2018 Aug; 20(4):e12896. PubMed ID: 29602266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective long-term study on primary CMV infections in adult liver transplant (D+/R-) patients after valganciclovir prophylaxis.
    Lautenschlager I; Loginov R; Mäkisalo H; Höckerstedt K
    J Clin Virol; 2015 Oct; 71():73-5. PubMed ID: 26318605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
    Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
    Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients.
    Lisboa LF; Preiksaitis JK; Humar A; Kumar D
    Transplantation; 2011 Nov; 92(9):1063-8. PubMed ID: 21878838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients.
    Ljungman P; Loré K; Aschan J; Klaesson S; Lewensohn-Fuchs I; Lönnqvist B; Ringdén O; Winiarski J; Ehrnst A
    Bone Marrow Transplant; 1996 Apr; 17(4):583-7. PubMed ID: 8722359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease.
    Bordon V; Bravo S; Van Renterghem L; de Moerloose B; Benoit Y; Laureys G; Dhooge C
    Transpl Infect Dis; 2008 Feb; 10(1):19-23. PubMed ID: 17511814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
    Murray BM; Subramaniam S
    Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing cytomegalovirus prophylaxis in renal transplantation: single center experience.
    Varga M; Remport A; Hídvégi M; Péter A; Kóbori L; Telkes G; Fazakas J; Gerlei Z; Sárváry E; Sulyok B; Járay J
    Transpl Infect Dis; 2005 Jun; 7(2):63-7. PubMed ID: 16150092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
    Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
    Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy.
    Harvala H; Stewart C; Muller K; Burns S; Marson L; MacGilchrist A; Johannessen I
    J Med Virol; 2013 May; 85(5):893-8. PubMed ID: 23508914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.
    Wiita AP; Roubinian N; Khan Y; Chin-Hong PV; Singer JP; Golden JA; Miller S
    Transpl Infect Dis; 2012 Jun; 14(3):248-58. PubMed ID: 22385394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
    Boillat Blanco N; Pascual M; Venetz JP; Nseir G; Meylan PR; Manuel O
    Transplantation; 2011 Jan; 91(2):251-5. PubMed ID: 21099744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
    Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
    Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of donor and recipient cytomegalovirus serology on long-term survival of heart transplant recipients.
    Mabilangan C; Preiksaitis JK; Cervera C;
    Transpl Infect Dis; 2019 Feb; 21(1):e13015. PubMed ID: 30358023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of higher dose and lower dose ganciclovir for cytomegalovirus prophylaxis in seropositive heart transplant recipients.
    Lee SO; Rim JH; Sung H; Kim SH; Choi SH; Lee CW; Yun TJ; Lee JW; Woo JH; Kim YS; Kim JJ
    Transpl Infect Dis; 2010 Feb; 12(1):31-7. PubMed ID: 19843292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts.
    Singh N; Wannstedt C; Keyes L; Mayher D; Tickerhoof L; Akoad M; Wagener MM; Cacciarelli TV
    Liver Transpl; 2008 Feb; 14(2):240-4. PubMed ID: 18236404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.